Background Patients with major depressive disorder (MDD) having active suicidal ideation
with intent require immediate treatment. Methods This double-blind study (ASPIRE II) …

Purpose/Background: Numerous health authority approvals of esketamine nasal spray,
combined with oral antidepressant, to treat depressive symptoms in adults with major …

Objective: To compare esketamine to placebo, each in addition to standard-of-care
treatment, for rapidly reducing major depressive disorder symptoms, including suicidal …

Objective: The authors compared the efficacy of standard-of-care treatment plus intranasal
esketamine or placebo for rapid reduction of symptoms of major depression, including …

Background About one-third of patients with depression fail to achieve remission despite
treatment with multiple antidepressants and are considered to have treatment-resistant …

Objective: Esketamine, the S-enantiomer of ketamine, was recently approved as a rapid-
acting intranasal therapy for depression and is currently under development for suicidality …

Objective: About one-third of patients with depression fail to achieve remission despite
treatment with multiple antidepressants. This study compared the efficacy and safety of …

Objective: To evaluate long-term safety and efficacy of esketamine nasal spray plus a new
oral antidepressant (OAD) in patients with treatment-resistant depression (TRD). Methods …

Suicide accounts for approximately 800,000 deaths per year globally. Previous research has
shown that intranasal esketamine and intravenous ketamine can rapidly decrease the …

Objectives This is a meta-analysis of randomized double-blind controlled-placebo trials
(RCTs) examining the effectiveness, tolerability, and safety of intranasal esketamine in …